NewAmsterdam Pharma Company NAMS Change In Fair Value Of Earnout
Change In Fair Value Of Earnout at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept nams:ChangeInFairValueOfEarnout.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's change in fair value of earnout.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's change in fair value of earnout?
- NewAmsterdam Pharma Company (NAMS) reported change in fair value of earnout of -$3.99M in Q1 2025.
- How has NewAmsterdam Pharma Company's change in fair value of earnout changed year-over-year?
- NewAmsterdam Pharma Company's change in fair value of earnout decreased by 145.9% year-over-year, from $8.7M to -$3.99M.
- What is the long-term trend for NewAmsterdam Pharma Company's change in fair value of earnout?
- Over 2 years (2022 to 2024), NewAmsterdam Pharma Company's change in fair value of earnout has grown at a 623.5% compound annual growth rate (CAGR), from $707K to $37.01M.
- What does change in fair value of earnout mean?
- This metric represents the periodic adjustment to the carrying value of contingent consideration liabilities related to acquisition agreements. It reflects changes in the estimated fair value of future payments owed to sellers based on the achievement of specific clinical or commercial milestones. Fluctuations in this value impact net income without affecting cash flow from operations.